Risperdal Trial for Gynecomastia Case Gets Underway in Philadelphia
The first trial for a Risperdal lawsuit has begun in Philadelphia state court, where a consolidated litigation currently includes more than 1,250 cases over the antipsychotic medication.
According to court documents, oral arguments were presented on January 23, 2015 by attorneys for the plaintiff, who allegedly grew “large female breasts” after taking Risperdal when he was 8 years old. Now 20, the autistic man from Alabama says his condition is permanent, aside from the mastectomy he underwent to remove the excess breast tissue that allegedly developed because of the medication.
On the Risperdal trial’s opening day, an attorney for the Johnson & Johnson subsidiary, Janssen Pharmaceuticals, also outlined their case for Pledger v. Janssen Pharmaceuticals to a 16-panel jury in the Philadelphia Court of Common Pleas.
Risperdal Safety Was Not Properly Tested by FDA, Risperdal Attorney Argues
Included in the claims filed in this lawsuit are allegations that the drug’s manufacturers were not forthcoming in its warning to the U.S. Food and Drug Administration (FDA), nor to doctors or patients, about the risk of gynecomastia and other complications that allegedly stem from its use.
“Many people think the FDA tests drugs,” said a Risperdal attorney for the plaintiff told jurors. “That’s not the case at all. They rely on pharmaceutical companies” to prove the safety of their medications.
The lawyer goes on to note an alleged study led by Janssen officials that found an 87 percent likelihood of elevated prolactin levels in children taking Risperdal. Male breast growth and premature lactation in young girls were among the problems recorded in the research.
According to another study, antipsychotic medication-related gynecomastia was found in 23 out of 419 men taking Risperdal, and 16 out of 419 other instances were “probably related to the drug,” the plaintiff’s counsel added.
It may come as a surprise that this party did not touch on a claim common to thousands of other Risperdal lawsuits—that Risperdal’s labeling does not adequately note its association with gynecomastia. Attorneys for Janssen jumped at this lack of mention, stating that the medication is approved for adults and that information about elevated prolactin levels and gynecomastia are clearly noted.
Consider a Risperdal Lawsuit
Call a Risperdal attorney today to find out if you are eligible to file a claim alleging male breast growth or another complication of the antipsychotic medication: (877) 779-1414.